BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29896197)

  • 1. Vaccination With Recombinant Filamentous
    Gomes-Neto JF; Sartorius R; Canto FB; Almeida TS; Dias AA; Barbosa CD; Melo GA; Oliveira AC; Aguiar PN; Machado CR; de Matos Guedes HL; Santiago MF; Nóbrega A; De Berardinis P; Bellio M
    Front Immunol; 2018; 9():1173. PubMed ID: 29896197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
    J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired innate immunity in Tlr4(-/-) mice but preserved CD8+ T cell responses against Trypanosoma cruzi in Tlr4-, Tlr2-, Tlr9- or Myd88-deficient mice.
    Oliveira AC; de Alencar BC; Tzelepis F; Klezewsky W; da Silva RN; Neves FS; Cavalcanti GS; Boscardin S; Nunes MP; Santiago MF; Nóbrega A; Rodrigues MM; Bellio M
    PLoS Pathog; 2010 Apr; 6(4):e1000870. PubMed ID: 20442858
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
    Front Immunol; 2019; 10():1456. PubMed ID: 31293599
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
    Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
    Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
    Chowdhury IH; Lokugamage N; Garg NJ
    Front Immunol; 2020; 11():595039. PubMed ID: 33414785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
    Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS
    Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Combined Deficiency of Immunoproteasome Subunits Affects Both the Magnitude and Quality of Pathogen- and Genetic Vaccination-Induced CD8+ T Cell Responses to the Human Protozoan Parasite Trypanosoma cruzi.
    Ersching J; Vasconcelos JR; Ferreira CP; Caetano BC; Machado AV; Bruna-Romero O; Baron MA; Ferreira LR; Cunha-Neto E; Rock KL; Gazzinelli RT; Rodrigues MM
    PLoS Pathog; 2016 Apr; 12(4):e1005593. PubMed ID: 27128676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice.
    Basso B; Cervetta L; Moretti E; Carlier Y; Truyens C
    Vaccine; 2004 May; 22(15-16):1868-72. PubMed ID: 15121297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy.
    Pratti JES; da Fonseca Martins AM; da Silva JP; Ramos TD; Pereira JC; Firmino-Cruz L; Oliveira-Maciel D; Vieira TSS; Lacerda LL; Vale AM; Freire-de-Lima CG; Gomes DCO; Saraiva EM; Rossi-Bergmann B; de Matos Guedes HL
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007146. PubMed ID: 30802247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.
    Barbosa RP; Filho BG; Dos Santos LI; Junior PA; Marques PE; Pereira RV; Cara DC; Bruña-Romero O; Rodrigues MM; Gazzinelli RT; Machado AV
    PLoS One; 2013; 8(4):e61795. PubMed ID: 23637908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic immunization based on the ubiquitin-fusion degradation pathway against Trypanosoma cruzi.
    Chou B; Hiromatsu K; Hisaeda H; Duan X; Imai T; Murata S; Tanaka K; Himeno K
    Biochem Biophys Res Commun; 2010 Feb; 392(3):277-82. PubMed ID: 20059980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection.
    Bafica A; Santiago HC; Goldszmid R; Ropert C; Gazzinelli RT; Sher A
    J Immunol; 2006 Sep; 177(6):3515-9. PubMed ID: 16951309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.
    Haolla FA; Claser C; de Alencar BC; Tzelepis F; de Vasconcelos JR; de Oliveira G; Silvério JC; Machado AV; Lannes-Vieira J; Bruna-Romero O; Gazzinelli RT; dos Santos RR; Soares MB; Rodrigues MM
    Vaccine; 2009 Sep; 27(41):5644-53. PubMed ID: 19635607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
    Basso B; Marini V
    Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells.
    Limon-Flores AY; Cervera-Cetina R; Tzec-Arjona JL; Ek-Macias L; Sánchez-Burgos G; Ramirez-Sierra MJ; Cruz-Chan JV; VanWynsberghe NR; Dumonteil E
    Vaccine; 2010 Oct; 28(46):7414-9. PubMed ID: 20850536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.
    Miyahira Y; Takashima Y; Kobayashi S; Matsumoto Y; Takeuchi T; Ohyanagi-Hara M; Yoshida A; Ohwada A; Akiba H; Yagita H; Okumura K; Ogawa H
    Infect Immun; 2005 Nov; 73(11):7356-65. PubMed ID: 16239534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
    Martinez-Campos V; Martinez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Seid CA; Hudspeth EM; Wei J; Liu Z; Kwityn C; Hammond M; Ortega-López J; Zhan B; Hotez PJ; Bottazzi ME; Dumonteil E
    Vaccine; 2015 Aug; 33(36):4505-12. PubMed ID: 26192358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From genome screening to creation of vaccine against Trypanosoma cruzi by use of immunoinformatics.
    Teh-Poot C; Tzec-Arjona E; Martínez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Dumonteil E
    J Infect Dis; 2015 Jan; 211(2):258-66. PubMed ID: 25070943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8(+) T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients.
    Egui A; Thomas MC; Morell M; Marañón C; Carrilero B; Segovia M; Puerta CJ; Pinazo MJ; Rosas F; Gascón J; López MC
    Mol Immunol; 2012 Oct; 52(3-4):289-98. PubMed ID: 22750229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.